跳至主要内容
临床试验/EUCTR2006-001879-38-DE
EUCTR2006-001879-38-DE进行中(未招募)不适用

Prospective, controlled, single-blind, bicentric, randomized study on the safety of HES 130/0.42 combined with a balanced electrolyte solution vs. 5% Albumin combined with an unbalanced electrolyte solution (NaCl 0.9%) in patients with compensated renal failure

B. Braun Melsungen AG0 个研究点开始时间: 2008年12月16日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Male or female patients older than 50 years of age
  • - Patients with compromised renal function, i.e. serum creatinine between 1.5 mg/dl and 3.0 mg/dl
  • - Patients scheduled for elective intervention
  • - Patients with an estimated intraoperative volume need of at least 1 L colloids
  • - Patients suffering from non-oliguric renal failure
  • - Provision of voluntary informed consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the informed consent form approved by the Institutional Ethics Committee (IEC) prior to all evaluations
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Patients of ASA-class > III
  • - Patients with daily urine output < 1L
  • - Patients on haemodialysis
  • - Patients receiving HES during the last 48 hours before first infusion of the investigational products
  • - Patients suffering from coagulation disorders (i.e. PTT > 60 sec)
  • - Patients with a hemoglobin < 9 g/dl
  • - Patients with known hypersensitivity to HES, albumin or any of the excipients
  • - Patients suffering from contraindications of the investigational products (i.e. Hyperhydration state including pulmonary oedema, renal failure with oliguria or anuria, intracranial haemorrhage, hyperkalaemia, severe hypernatraemia or severe hyperchloraemia, severely impaired hepatic fuction, congestive heart failure)
  • - Simultaneous participation in another clinical trial
  • - Emergencies
  • - Patients incapable to give informed consent (e. g. patients with dementia, psychiatric diseases or suffering from conditions associated with lack of conciousness)

研究者

相似试验

已完成
不适用
Prospective, open, controlled, single-blind, multicenter study to demonstrate the effectiveness of the innovative ankle support FastProtect Malleo for secondary prevention after distortion of the upper ankle in competitive athletesRecurrent dislocation, ankle, foot and toesM24.47
DRKS00018817Julius Zorn GmbH69
进行中(未招募)
不适用
Singleblind, randomized, verum-controlled, multicentric study to confirm the non-inferiority of Leukichtan Gel versus Betaisodona Salbe in the treatment of cuts, abrasions and burns
EUCTR2007-000532-47-DEICHTHYOL-GESELLSCHAFT Cordes, Hermanni & Co. (GmbH & Co.) KG
进行中(未招募)
1 期
Study on the efficacy of laser treatment using a dye as an enhancer
EUCTR2009-009956-20-DEFree State of Bavaria rep. by the Univ. of Regensburg, rep. by the Regensburg Univ. Hospital
进行中(未招募)
1 期
Doppelblinde, prospektive, randomisierte, monozentrische, placebo-kontrollierte Pilotstudie zur Wirksamkeit und Sicherheit von Moxifloxacin in der Prophylaxe der Bakteriämie nach Hochdosis-Chemotherapie und Transplantation peripherer Stammzellen - Moxifloxacin ProphylaxeDie Inzidenz von Fieber und Infektionen nach Hochdosis-Chemotherapie und autologer Stammzelltransplantation beträgt zwischen 40 und 100%. Die Antibiotika-Prophylaxe ist daher fester Bestandteil der Protokolle zur antineoplastischen Therapie. Aufgrund seines gegenüber älteren Chinolonen verbesserten Wirkspektrums und seines pharmaokinetischen Profils soll die prophylaktische Behandlung mit Moxifloxacin zur Verminderung von Bakteriämien untersucht werden.
EUCTR2005-003271-21-DEniversität zu Köln66
进行中(未招募)
不适用
Prospective, monocentric, controlled, randomized, double-blind study to comparetwo different propofol emulsions regarding tolerability and injection pain during the induction of anesthesia in adultsreduction of injection pain during induction of anaesthesia
EUCTR2007-003571-39-DEB. Braun Melsungen AG